EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.

被引：0
|
作者：
Emery, M. G. [1 ]
Gibbs, J. P. [1 ]
Slatter, J. G. [2 ]
Hamilton, L. [3 ]
Wasserman, S. M. [1 ]
Geller, M. [1 ]
Dias, C. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Seattle, WA USA
[3] Amgen Ltd, Uxbridge, Middx, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-034
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [31] Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience
    Paquette, Martine
    Faubert, Simon
    Saint-Pierre, Nathalie
    Baass, Alexis
    Bernard, Sophie
    JOURNAL OF CLINICAL LIPIDOLOGY, 2023, 17 (01) : 142 - 149
  • [32] Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE-/- Mice
    Gu, Lili
    Gong, Yaqin
    Zhao, Cheng
    Wang, Yue
    Tian, Qinghua
    Lei, Gaoxin
    Liang, Yalin
    Zhao, Wenfeng
    Tan, Shuhua
    MOLECULES, 2019, 24 (22):
  • [33] Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency
    Janis, Minna T.
    Tarasov, Kirill
    Ta, Hung Xuan
    Suoniemi, Matti
    Ekroos, Kim
    Hurme, Reini
    Lehtimaki, Terho
    Paiva, Hannu
    Kleber, Marcus E.
    Maerz, Winfried
    Prat, Annik
    Seidah, Nabil G.
    Laaksonen, Reijo
    ATHEROSCLEROSIS, 2013, 228 (02) : 380 - 385
  • [34] REAL-WORLD DATA ON THE COMPARISON OF LDL-C LOWERING EFFECTS BETWEEN ALIROCUMAB AND EVOLOCUMAB
    Lin, D. -Y.
    Tsai, C. -L.
    Chuang, J. -Y.
    Liang, C. -H.
    Chen, Y. -H.
    Chang, Y. -H.
    Yeh, H. -I.
    Lin, C. -F.
    ATHEROSCLEROSIS, 2022, 355 : E300 - E300
  • [35] A review of PCSK9 inhibition and its effects beyond LDL receptors
    Dixon, Dave L.
    Trankle, Cory
    Buckley, Leo
    Parod, Eric
    Carbone, Salvatore
    Van Tassell, Benjamin W.
    Abbate, Antonio
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (05) : 1073 - 1080
  • [36] PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/WITHOUT STATIN BACKGROUND
    Robinson, J. G.
    Farnier, M.
    Kastelein, J. J.
    Roth, E. M.
    Taskinen, M. R.
    Colhoun, H. M.
    Brunet, A.
    DiCioccio, A. T.
    Lecorps, G.
    Pordy, R.
    Baccara-Dinet, M. T.
    Cannon, C. P.
    ATHEROSCLEROSIS, 2016, 252 : E231 - E231
  • [37] Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia
    Leiter, Lawrence
    Teoh, Hwee
    Kallend, David
    Wright, R. Scott
    Landmesser, Ulf
    Wijngaard, Peter L.
    Kastelein, John J.
    Ray, Kausik K.
    DIABETES, 2018, 67
  • [38] Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression
    Gong, Yingyun
    Ma, Yizhe
    Ye, Zhengqin
    Fu, Zhenzhen
    Yang, Panpan
    Gao, Beibei
    Guo, Wen
    Hu, Dandan
    Ye, Jingya
    Ma, Shuai
    Zhang, Fan
    Zhou, Li
    Xu, Xinyu
    Li, Zhong
    Yang, Tao
    Zhou, Hongwen
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 76 : 32 - 41
  • [39] Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment
    Turncliff, RZ
    Dunbar, JL
    Dong, QM
    Silverman, BL
    Ehrich, EW
    Dilzer, SC
    Lasseter, KC
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11): : 1259 - 1267
  • [40] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus
    Kosmas, Constantine E.
    Sourlas, Andreas
    Bouza, Kyriaki V.
    DeJesus, Eddy
    Silverio, Delia
    Montan, Peter D.
    Guzman, Eliscer
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (07)
12345